Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Association Between the Quantitative Assessment of Schistocytes in Peripheral Blood Smear and Prognosis of Patient Initially Diagnosed as HELLP Syndrome.

NCT03246542 is registered in ClinicalTrials.gov with AYMAN ABDELKADER MOHAMED ABDELKADER as lead sponsor.

NCT NCT03246542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03246542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Association Between the Quantitative Assessment of Schistocytes in Peripheral Blood Smear and Prognosis of Patient Initially Diagnosed as HELLP Syndrome.
Lead sponsor
AYMAN ABDELKADER MOHAMED ABDELKADER
Phase
Observational
Overall status
Completed
Start date
January 1, 2015
Completion date
June 1, 2016
Enrollment
100 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hellp syndrome, microangiopathy, pre-eclampsia, severe